Literature DB >> 11023662

Interleukin 8, neutrophil-activating peptide-2 and GRO-alpha bind to and elicit cell activation via specific and different amino acid residues of CXCR2.

J A Katancik1, A Sharma, E de Nardin.   

Abstract

The objective of this investigation was to determine the amino acid residues of the human neutrophil CXC chemokine receptor-2 (CXCR2) that are critical for binding the ligands interleukin 8 (IL-8), neutrophil-activating peptide-2 (NAP-2), and growth-related protein alpha (GROalpha) and critical for receptor-mediated signal transduction. Charged residues of the amino terminus and the first extracellular loop of CXCR2 were targeted for point mutagenesis studies. Seven separate CXCR2 mutants (Glu7, Asp9, Glu12, Asp13, Lys108, Asn110, and Lys120, all to Ala) were generated. Based on the Scatchard analysis of radioligand binding studies, the following amino acids were deemed critical for ligand binding: (i) Asp9, Glu12, Lys108, and Lys120 for IL-8 and (ii) Glu7, Asp9, and Glu12 for GROalpha. Point mutations in the amino terminus domain (Asp9 and Glu12) and the first extracellular loop (Lys108, Asn110, and Lys120) of CXCR2 reduced cell activation to all three ligands as measured by changes in intracellular calcium concentration. In conclusion, high-affinity binding of IL-8, NAP-2, and GROalpha to CXCR2 involves interaction with specific and different amino acid residues of CXCR2. Furthermore, we propose that the CXCR2 amino acid residues required for cell activation are not necessarily the same residues required for ligand binding. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11023662     DOI: 10.1006/cyto.2000.0742

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  21 in total

Review 1.  Structural basis of chemokine receptor function--a model for binding affinity and ligand selectivity.

Authors:  Lavanya Rajagopalan; Krishna Rajarathnam
Journal:  Biosci Rep       Date:  2006-10       Impact factor: 3.840

2.  Phage display and hybridoma generation of antibodies to human CXCR2 yields antibodies with distinct mechanisms and epitopes.

Authors:  Christine J Rossant; Danielle Carroll; Ling Huang; John Elvin; Frances Neal; Edward Walker; Joris J Benschop; Eldar E Kim; Simon T Barry; Tristan J Vaughan
Journal:  MAbs       Date:  2014       Impact factor: 5.857

3.  Functional anatomy of the full-length CXCR4-CXCL12 complex systematically dissected by quantitative model-guided mutagenesis.

Authors:  Bryan S Stephens; Tony Ngo; Irina Kufareva; Tracy M Handel
Journal:  Sci Signal       Date:  2020-07-14       Impact factor: 8.192

Review 4.  Pancreatic islet inflammation: an emerging role for chemokines.

Authors:  J Jason Collier; Tim E Sparer; Michael D Karlstad; Susan J Burke
Journal:  J Mol Endocrinol       Date:  2017-04-18       Impact factor: 5.098

5.  Chemokine CXCL1 dimer is a potent agonist for the CXCR2 receptor.

Authors:  Aishwarya Ravindran; Kirti V Sawant; Jose Sarmiento; Javier Navarro; Krishna Rajarathnam
Journal:  J Biol Chem       Date:  2013-03-11       Impact factor: 5.157

6.  Mutational Analysis of Atypical Chemokine Receptor 3 (ACKR3/CXCR7) Interaction with Its Chemokine Ligands CXCL11 and CXCL12.

Authors:  Besma Benredjem; Mélanie Girard; David Rhainds; Geneviève St-Onge; Nikolaus Heveker
Journal:  J Biol Chem       Date:  2016-11-14       Impact factor: 5.157

Review 7.  What Do Structures Tell Us About Chemokine Receptor Function and Antagonism?

Authors:  Irina Kufareva; Martin Gustavsson; Yi Zheng; Bryan S Stephens; Tracy M Handel
Journal:  Annu Rev Biophys       Date:  2017-05-22       Impact factor: 12.981

Review 8.  How do chemokines navigate neutrophils to the target site: Dissecting the structural mechanisms and signaling pathways.

Authors:  Krishna Rajarathnam; Michael Schnoor; Ricardo M Richardson; Sudarshan Rajagopal
Journal:  Cell Signal       Date:  2018-11-19       Impact factor: 4.315

9.  A combination of in vitro techniques for efficient discovery of functional monoclonal antibodies against human CXC chemokine receptor-2 (CXCR2).

Authors:  Ronald S Boshuizen; Catherine Marsden; Johan Turkstra; Christine J Rossant; Jerry Slootstra; Clive Copley; Klaus Schwamborn
Journal:  MAbs       Date:  2014       Impact factor: 5.857

10.  Inhibition of CXCR2 signaling promotes recovery in models of multiple sclerosis.

Authors:  A E Kerstetter; D A Padovani-Claudio; L Bai; R H Miller
Journal:  Exp Neurol       Date:  2009-07-17       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.